GlobeNewswire

Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

Del

Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels

Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end

VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today announced that clinical data from a metreleptin study assessing weight loss in overweight and obese adults with low leptin levels will be featured in a poster presentation at the American Diabetes Association's (ADA) 78th Scientific Sessions, being held June 22-26, 2018 in Orlando.  

The study, titled "Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults With Low Leptin Levels," was conducted in adults with low baseline leptin, defined as <16 ng/mL in females and <5 ng/mL in males, and Body Mass Index (BMI) levels between 27.5 and 38.0 kg/m2. The study assessed weight levels in these patients (n=267) following once-daily subcutaneous doses of 10 mg metreleptin, 20 mg metreleptin, or placebo over 24 weeks.

Patients with low leptin who received the 10 mg dose (n=74) or 20 mg dose (n=72) of metreleptin showed greater decreases in weight from baseline over the 24-week period compared to patients who received placebo (n=111). In addition, patients treated with the 20 mg dose displayed statistically significant weight loss by weeks 8-10, regardless of whether they had the highest or the lowest baseline levels of leptin. Notably, weight loss was maintained across dose levels for the entire six-month duration of the study, and patients with the lowest leptin levels benefitted most from metreleptin treatment.

Metreleptin was generally well-tolerated at both doses. The most common adverse events (AEs) were injection-site reactions, headache, fatigue, gastrointestinal events, and upper respiratory tract infection. Most AEs were mild to moderate in severity.

"We are very pleased with the data indicating metreleptin's activity in a population of overweight and obese adults with low baseline leptin levels, who are in need of options to help them lose weight and control the metabolic complications associated with their disease," said Dr. Murray Stewart, Executive Vice President, Head of Research and Development for Novelion. "This is encouraging because it suggests that leptin replacement shows promise in the treatment of overweight and obese adult patients suffering from hypoleptinemic metabolic disorders who are characterized by very low leptin levels. Based on this data, we look forward to initiating a Phase 2 proof of concept study in HMD before year-end."

The study was conducted by Alex DePaoli, M.D., Alison Long, M.D., Ph.D., Gregory Fine, M.S., Murray Stewart, M.D., and Sir Stephen O'Rahilly FRS FRCP.

Presentation Details

Title: Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults With Low Leptin Levels
Presenter:
 Dr. Alex M. DePaoli, Sansum Diabetes Research Institute
Abstract Number: 296-LB
Date: 
Monday, June 25, 2018 at 12:00 PM 

About Hypoleptinemic Metabolic Disorder (HMD)

HMD is a spectrum of metabolic sequelae secondary to underlying leptin deficiency.  These patients differ from epidemic "lifestyle" diseases such as common obesity, type 2 diabetes mellitus/insulin resistance and dyslipidemia, in that low leptin may be the driver of the metabolic dysfunction. Metreleptin is not intended to treat common obesity or adult onset diabetes; however, it may be a potential treatment option in a small segment of this population, specifically those patients with very low leptin levels.

Metreleptin is not currently approved for use in HMD. Metreleptin is only approved by the U.S. Food and Drug Administration as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. In addition, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorization, under exceptional circumstances, for metreleptin as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized LD or acquired generalized LD in adults and children 2 years of age and above; or with confirmed familial partial LD or acquired partial LD, in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.

IMPORTANT SAFETY INFORMATION

Highlights of Safety Information from U.S. Prescribing Information for MYALEPT (metreleptin U.S. brand name)

WARNING:  RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF LYMPHOMA

See  full prescribing information  for complete boxed warning.

Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences are not well characterized but could include inhibition of endogenous leptin action and/or loss of MYALEPT efficacy. Worsening metabolic control and/or severe infection have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients with severe infections or loss of efficacy during MYALEPT treatment.

T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with MYALEPT. Carefully consider the benefits and risks of MYALEPT treatment in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy.

MYALEPT is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYALEPT REMS PROGRAM.

CONTRAINDICATIONS

MYALEPT is contraindicated in general obesity not associated with congenital leptin deficiency and in patients with hypersensitivity to metreleptin.

WARNINGS AND PRECAUTIONS

Anti-metreleptin antibodies with neutralizing activity: Could inhibit endogenous leptin action and/or result in loss of MYALEPT efficacy.  Test for neutralizing antibodies in patients with severe infections or loss of efficacy during MYALEPT treatment.

T-cell lymphoma:  Carefully consider benefits and risks of treatment with MYALEPT in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy.

Hypoglycemia:  A dose adjustment, including possible large reductions, of insulin or insulin secretagogue may be necessary. Closely monitor blood glucose in patients on concomitant insulin, or insulin secretagogue.

Autoimmunity:  Autoimmune disorder progression has been observed in patients treated with MYALEPT.  Carefully consider benefits and risks of MYLEPT treatment in patients with autoimmune disease.

Hypersensitivity reactions (e.g., anaphylaxis, urticaria or generalized rash) have been reported.  Patients should promptly seek medical advice about discontinuation of MYALEPT if a hypersensitivity reaction occurs.

Benzyl Alcohol Toxicity:  Preservative-free Water for Injection is recommended for use in neonates and infants.

ADVERSE REACTIONS

Most common adverse reactions (> / = 10%) in clinical trials were headache, hypoglycemia, decreased weight, and abdominal pain.

USE IN SPECIAL POPULATIONS

MYALEPT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  No adequate and well-controlled studies have been conducted with metreleptin in pregnant women. Nursing Mothers should discontinue drug or nursing.

For additional information, please see the  U.S. Prescribing Information  including Box Warning for MYALEPT.

About Novelion Therapeutics

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a rare disease product portfolio through its subsidiary, Aegerion Pharmaceuticals, Inc. The Company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.

Forward Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Novelion within the meaning of applicable laws and regulations and constitute "forward-looking information" within the meaning of applicable securities laws. Any statements contained herein which do not describe historical facts, including statements regarding our plans to initiate a Phase 2 proof of concept study in HMD and our expectations and beliefs about leptin replacement showing promise in the treatment of overweight and obese adult patients suffering from hypoleptinemic metabolic disorders who are characterized by very low leptin levels, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, that clinical data, such as the data included in the poster presentation, does not mean that metreleptin will have success in the planned Phase 2 proof of concept study in HMD or subsequent, later stage clinical trials and those risks identified in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in our Annual Report on Form 10-K filed on March 16, 2018, and subsequent filings, with the SEC, available on the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect our results of operations and cash flows, which would, in turn, have a significant and adverse impact on our stock price. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, we undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. 

Investors and others should note that we communicate with our investors and the public using our company website, www.novelion.com, including, but not limited to, company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference call transcripts and webcast transcripts. The information that we post on this website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

CONTACT:

Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novelion Therapeutics Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Continued Growth for INVNT Following Client Wins, An Expanded Offering, New Offices and Fresh Talent23.4.2019 15:20:00 CESTPressemelding

NEW YORK, NY, April 23, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, achieved a number of milestones in 2018, a move that saw its revenues reach over $54 million, exceeding forecasts and representing a 30% increase on the previous year. With a number of impressive new clients and continued expansion in the works, the agency is targeting $62 million in revenue for 2019. INVNT secured new clients including Microsoft, Facebook, Pfizer, Xero, TEDxSydney, New Relic and Mary Kay last year. They grew many accounts from local to global, a move that now sees INVNTrs deliver campaigns for clients across the globe. INVNT also exceeded existing clients’ expectations in 2018, delivering compelling live brand storytelling™ moments for the likes of General Motors, Grant Thornton, Merck, PepsiCo, Samsung and Subway. Scott Cullather, CEO, INVNT explains: “Our tremendous growth is due to a combination of our team’s ability to develop compelling live brand stories that are

Always Powered by Passion: Meizu 16s Flagship Smartphone Unveiled, Snapdragon 855 and 48MP OIS Dual Camera23.4.2019 15:00:00 CESTPressemelding

Zhuhai, April 23, 2019 (GLOBE NEWSWIRE) -- Zhuhai, 23rd April 2019 -- Meizu Technology Co., Ltd (Meizu) has officially introduced its latest flagship 16s and will be available for sale in China on 28th April starting at 3198 RMB. The signature Meizu Design brings a sense of elegance to the phone. Powered by Qualcomm Snapdragon 855, the 16s features a 48MP + OIS Dual Camera, making it the best device to use for everyday shots. The latest flagship 16s is a testament to the 16 years’ experience in phone making of Meizu. The company has spared no effort with 100% dedication in producing premium phone for quality-seeking users, despite the size of the target market. 16s is a product that reflects ‘100% efforts for 1% selected Products’, Meizu strives for excellence with passion. Meizu 16s comes in Pearl White, Carbon Black, and Phantom Blue, of which 6+128G, 8+128G and 8+256G will be respectively priced at 3198 RMB, 3498 RMB and 3998 RMB, and will be available on Meizu official website for

iGrafx Announces Cohesive RPA Accelerator Solution23.4.2019 14:48:00 CESTPressemelding

Combines Core Capabilities from iGrafx, myInvenio, Servicetrace, UiPath and BP3 Global Dallas, TX, April 23, 2019 (GLOBE NEWSWIRE) -- Today at the iNNOVATE 2019 conference, iGrafx unveiled the industry’s first end-to-end RPA Accelerator solution, enabling enterprises to identify, assess, prioritize, execute and govern robotic process automation (RPA) projects. The turnkey package includes a new version of the iGrafx Platform, along with process mining from myInvenio, RPA bots from either UiPath or Servicetrace and professional services from BP3. For the first time ever, Center of Excellence leaders can access the combined, best-of-breed capabilities from a single source for a single price. “Our customers tell us that they have a huge challenge understanding what to optimize and automate in order to achieve real digital transformation,” said Ryan Tognazzini, CEO at iGrafx. This is a challenge that is also iterated again and again by industry experts. In a recent Forrester report, Rob Ko

MJBizDaily Introduces MJBizDaily European Cannabis Symposium, Copenhagen, Denmark, May 623.4.2019 11:00:00 CESTPressemelding

DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- The producers of America’s oldest and largest cannabis trade show, Marijuana Business Conference & Expo (MJBizCon), introduce MJBizDaily’s European Cannabis Symposium in Denmark, Copenhagen. MJBizDaily’s European Cannabis Symposium will take place on Monday, May 6 at the Scandic Copenhagen Hotel in Copenhagen, Denmark. Leaders in the business, research and legislation of Europe’s medical marijuana and hemp market will gather for an intensive one-day conference offering educational sessions on the latest in tech, scientific research, and potential impacts on global markets. Table top exhibitors and an opening cocktail reception on Sunday, May 5 will also offer invaluable networking opportunities. “Regulated, normalized cannabis programs are just now starting to come into their own across Europe. As those government, industry and scientific ties continue to strengthen across the continent, the time is right to provide an in-person platform for e

LeddarTech Appoints Richard LaRue, a Seasoned Corporate International Lawyer, to its Executive Team23.4.2019 06:58:00 CESTPressemelding

LeddarTech Increases Automotive LiDAR Expertise with a Research and Development Team in Toronto, Canada LeddarTech enhances its senior management leadership team through the appointment of a Chief Legal Officer and further accelerates time to market by announcing the official opening of the Automotive Center of Excellence R&D facility in Toronto, Canada. QUEBEC CITY, April 23, 2019 (GLOBE NEWSWIRE) -- LeddarTech®, an industry leader providing the most versatile and scalable auto and mobility LiDAR platform ™, is pleased to announce the appointment of Mr. Richard LaRue as Chief Legal Officer. Mr. LaRue has worked extensively with software and biotech companies, as well as start-ups, in all aspects of their business, including their constitution, the negotiation, and drafting of international agreements and their equity and debt financing. He has practiced in these areas across Canada, Europe, and the U.S. “I look forward to leveraging my international experience in corporate law, financ

WillScot to Announce First Quarter 2019 Results on May 2, 201922.4.2019 22:04:00 CESTPressemelding

BALTIMORE, April 22, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC) today announced that it will release its first quarter 2019 financial results on Thursday, May 2, 2019 after the markets close. President and Chief Executive Officer, Bradley Soultz, and Chief Financial Officer, Timothy Boswell will host a conference call and webcast on Friday, May 3, 2019 at 10:00 a.m. EDT to discuss the results. The live call can be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (International). A live webcast will also be accessible via the “Events & Presentations” section of the Company’s Investor Relations website https://investors.willscot.com. An archived version of the webcast will be available for 60 days following the call. About WillScot Corporation Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corpora